Gilead Sciences, Inc. (GILD) Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma
6/17/2013 9:25:03 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LUGANO, Switzerland--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6 percent, with a median duration of response at this interim analysis of 11.9 months. Detailed study results will be presented this Thursday during an oral session at the 12th International Conference on Malignant Lymphoma in Lugano, Switzerland (Abstract #064bis).
Help employers find you! Check out all the jobs and post your resume.
comments powered by